Jump to navigation Jump to search
|Preferred IUPAC name
3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||401.44 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Vosaroxin (AG-7352, SPC-595, SNS 595, voreloxin) is a topoisomerase II inhibitor causing site-selective DNA damage. It is under phase III clinical trial investigation for acute myelogenous leukemia (AML) and ovarian cancer sponsored by Sunesis.
Mechanism of action
Vosaroxin is a naphthyridine analog of the anticancer quinolone derivatives (AQDs), a class of compounds that has not been used previously for the treatment of cancer. Topoisomerase II enzymes are essential for the survival of eukaryotic cells. Vosaroxin hinders the reunion of topoisomerase II-induced double-strand breaks at selective sites in DNA, resulting in G2 arrest and cell death by apoptosis.
- ^ "Vosaroxin". Selleck Chemicals.
- ^ "Vosaroxin (Formerly Voreloxin)". Sunesis.
- Articles without EBI source
- Articles without KEGG source
- Pages using collapsible list with both background and text-align in titlestyle
- Articles containing unverified chemical infoboxes
- Articles with short description
- Short description matches Wikidata
- Topoisomerase inhibitors
- All stub articles
- Antineoplastic and immunomodulating drug stubs